Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: Two randomized controlled trials

Menopause

Volumn 20, Issue 10, 2013, Pages 1027-1035

  Simon, James A ^a   Portman, David J ^b   Kaunitz, Andrew M ^c   Mekonnen, Hana ^d   Kazempour, Kazem ^d   Bhaskar, Sailaja ^e   Lippman, Joel ^e  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Columbus Center for Women's Health Research ^*  (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Amarex Clinical Research   (United States)

^e Noven Pharmaceuticals Inc   (United States)

Author keywords

Hot flashes; Menopause; Nonhormonal; Paroxetine mesylate; Selective serotonin reuptake inhibitor; Vasomotor symptoms

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LABORATORY TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE TWITCH; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VASOMOTOR DISORDER; VITAL SIGN;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PAROXETINE; PLACEBOS; POSTMENOPAUSE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84885176757     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e3182a66aa7     Document Type: Article

References (30)

1. The North American Menopause Society. Treatment of menopauseassociated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11: 11-33.
2. Williams RE, Kalilani L, DiBenedetti DB, et al. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric 2008;11: 32-43.
3. US National Institutes of Health. NIH State-of-the-Science Conference Statement on Management of Menopause-Related Symptoms, vol 22, no Bethesda, MD: US Department of Health and Human Services, 2005: 21-23.
4. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas 2007;58: 348-358.
5. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013;16: 235-239.
6. Van Dole KB, Williams RE, Brown RS, Gaynes B, Devellis R, Funk MJ. Longitudinal association of vasomotor symptoms and psychosocial outcomes among postmenopausal women in the United States: a populationbased study. Menopause 2010;17: 917-923.
7. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19: 257-271.
8. Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011;71: 287-304.
9. Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS. Paroxetine mesylate: comparable to paroxetine hydrochloride? Exp Opin Pharmacother 2010;11: 185-193.
10. Joffe H. Low-dose mesylate salt of paroxetine (LDMP) in treatment of vasomotor symptoms (VMS) in menopause. Paper presented at: Annual Clinical Meeting of the American College of Obstetricians and Gynecologists; 2012; San Diego, CA.
11. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol 1985;22: 293-312.
12. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23: 117-125.
13. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77: 1207-1218.
14. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms. Recommendations for clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338. pdf. Accessed January 21, 2013.
15. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007;10: 73-84.
16. Gelenberg AJ, Freeman MP, Markowitz JC. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. Arlington, VA: American Psychiatric Association, 2010. Available at: http://psycho.silverchair. com/pracGuide/PracticePDFs/PG- Depression3rdEd.pdf. Accessed January 21, 2013.
17. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002;14: 175-182.
18. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
19. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstet Gynecol 2006;108: 33-40.
20. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012;120: 595-603.
21. Johnston J. Managing the menopause: practical choices faced in primary care. Climacteric 2011;14: 8-12.
22. Imai A, Matsunami K, Takagi H, Ichigo S. New generation nonhormonal management for hot flashes. Gynecol Endocrinol 2013;29: 63-66.
23. Thacker HL. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. J Womens Health 2011;20: 1007-1016.
24. Pachman DR, Jones JM, Loprinzi CL. Management of menopauseassociated vasomotor symptoms: current treatment options, challenges and future directions. Int J Womens Health 2010;2: 123-135.
25. Data on file (based on research conducted by IMS NPA Market Dynamics), 2012, Noven Pharmaceuticals, Inc.
26. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 155-164.
27. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360: 1851-1861.
28. Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat: evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 1986;25: 1307-1313.
29. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
30. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166: 357-365.